Go back to your search

Ophthalmic R&D Company - REF:83587


The company is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eye care practitioners and patients around the world.

The company has two products under development, NCX 470 for glaucoma and NCX 4751 for blepharitis. The glaucoma drug is to be launched in 2024 and sales of over €450 million are projected in the United States and other major markets. NCX 470 targets the $1.4 Billion U.S. glaucoma PGA market.

  • Capital raise: £10 million GBP
  • Headquarters: Paris, France
  • Type of entity: Publicly traded company
  • Use of proceeds: Securing FDA approval for
    NCX 470 and NCX 4751 in the United States.
  • USPs: Well established company, very large
    target market, highly experienced team.
  • Type of investment: Equity
  • Geography: Europe/ US
  • Annual revenue: €14.4m EUR
  • Min. ticket size: £500K GB

Price: 12.066.100€

Type Property Included
Status For sale
Franchise Yes
Price 12.066.100€
Revenue No Traslate this String
Cash Flow No Traslate this String

Professional Contact

1- iDealBiz Direct Contact

... Pay Before Worldwide

Professional Contact

1- iDealBiz Direct Contact

... Pay Before Worldwide

    Ask for information

    Advertisement associated with Mediator. You will be contacted by:

    Property information

    Business operations

    Living Accomodations Yes


    Relocatable: Yes
    Owner Financing Available: Yes